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Abstract
Background: De-escalation is strongly recommended for antibiotic stewardship. No studies have addressed this
issue in the context of health care-associated intra-abdominal infections (HCIAI). We analyzed the factors that could
interfere with this process and their clinical consequences in intensive care unit (ICU) patients with HCIAI.
Methods: All consecutive patients admitted for the management of HCIAI who survived more than 3 days
following their diagnosis, who remained in the ICU for more than 3 days, and who did not undergo early
reoperation during the first 3 days were analyzed prospectively in an observational, single-center study in a tertiary
care university hospital.
Results: Overall, 311 patients with HCIAI were admitted to the ICU. De-escalation was applied in 110 patients
(53 %), and no de-escalation was reported in 96 patients (47 %) (escalation in 65 [32 %] and unchanged regimen in 31
[15 %]). Lower proportions of Enterococcus faecium, nonfermenting Gram-negative bacilli (NFGNB), and multidrug-
resistant (MDR) strains were cultured in the de-escalation group. No clinical difference was observed at day 7 between
patients who were de-escalated and those who were not. Determinants of de-escalation in multivariate analysis were
adequate empiric therapy (OR 9.60, 95 % CI 4.02–22.97) and empiric use of vancomycin (OR 3.39, 95 % CI 1.46–7.87),
carbapenems (OR 2.64, 95 % CI 1.01–6.91), and aminoglycosides (OR 2.31 95 % CI 1.08–4.94). The presence of NFGNB
(OR 0.28, 95 % CI 0.09–0.89) and the presence of MDR bacteria
(OR 0.21, 95 % CI 0.09–0.52) were risk factors for non-de-escalation. De-escalation did not change the overall duration of
therapy. The risk factors for death at day 28 were presence of fungi (HR 2.64, 95 % CI 1.34–5.17), Sequential Organ
Failure Assessment score on admission (HR 1.29, 95 % CI 1.16–1.42), and age (HR 1.03, 95 % CI 1.01–1.05). The survival
rate expressed by a Kaplan-Meier curve was similar between groups
(log-rank test p value 0.176).
Conclusions: De-escalation is a feasible option in patients with polymicrobial infections such as HCIAI, but MDR
organisms and NFGNB limit its implementation.
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Background
The modern concept of reducing both the spectrum of
antimicrobial therapy and its potential to promote resist-
ance [1], usually called de-escalation, is strongly recom-
mended in all of the recently published guidelines for
antibiotic stewardship [2, 3]. Several definitions have
been used to describe this process [1, 4–7]. Despite the
limited evidence, de-escalation has been recommended
to decrease the likelihood of emergence of resistant or-
ganisms [8], to optimize activity, and to reduce toxicity
and costs [3].
Two types of critically ill patients have been investi-
gated: cohorts with a specific disease—mainly ventilator-
associated pneumonia (VAP) [5, 9–13]—and large mixed
populations with severe sepsis or septic shock or pa-
tients who require emergency empiric antibiotic therapy
[4, 14–19]. In a recent systematic review, Tabah et al.
identified isolation of multiresistant pathogens, polymicro-
bial infections, and intra-abdominal infections as factors
negatively associated with de-escalation [20]. Only a few
studies have addressed this issue in the context of intra-
abdominal infections [4, 14, 18, 21, 22]. The high fre-
quency of polymicrobial infection [23, 24] and multidrug-
resistant (MDR) organisms [23, 24] as well as the presence
of fungi [17, 25] in this setting might raise specific con-
cerns, especially in health care-associated intra-abdominal
infections (HCIAI).
The purpose of the present study was to analyze the
frequency of de-escalation, the factors that could inter-
fere with this process, and their clinical consequences




From January 1999 through December 2011, all con-
secutive patients admitted to our ICU for the manage-
ment of HCIAI were prospectively included in a
database and their medical charts were retrospectively
reviewed. The study was approved by the local institutional
review board (CEERB CHU Bichat Paris VII University,
APHP, Paris, France), which waived the need for signed
informed consent.
Selection of cases and inclusion criteria
Postoperative peritonitis was defined as the first macro-
scopic findings of intra-abdominal infection combined
with positive fluid culture yielding at least one micro-
organism (bacteria or fungi) at the time of reoperation
(day 0) following a first abdominal surgery [24]. Several
patients had to be excluded from the analysis due to
early change in their clinical status before de-escalation
could be instituted: patients who died during the first
3 days following surgery (microbiologic results not yet
obtained), those who were discharged during the first
3 days (incapacity to adequately follow clinical outcome
and antibiotic therapy), and those who underwent early
reoperation during the first 3 days (high proportion of
persistent infection and prolonged antibiotic therapy).
Similarly, we excluded patients with negative microbio-
logic samples, since the concept of de-escalation is ques-
tionable and the interpretation of the results is difficult.
In these patients, empiric anti-infective therapy was
discontinued. Drainage of abscesses, debridement of in-
fected and necrotic tissues, abdominal cavity cleansing,
irrigation, and definitive control of the source of con-
tamination were performed according to the surgical
principles used for the management of abdominal sepsis
[26]. Ostomy was preferred to primary anastomosis. No
open-wound management was performed, and the abdo-
men was not irrigated after surgery.
Microbiologic data
Peritoneal fluid samples were systematically collected
during surgery and were immediately sent to the bacteri-
ology laboratory [24]. Cultures were performed with identi-
fication and susceptibility testing for Gram-positive and
Gram-negative aerobe bacteria, anaerobes, and fungi. Anti-
biotic susceptibility was determined for each organism by
the disk diffusion method, according to the criteria of the
Antibiogram Committee of the French Society for Micro-
biology [27]. MDR bacteria were defined as those resistant
to three or more antimicrobial classes [28]: methicillin-
resistant Staphylococcus aureus and methicillin-resistant
coagulase-negative staphylococci; ampicillin-resistant
enterococci; Enterobacteriaceae producing an extended-
spectrum β-lactamase or producing a derepressed cepha-
losporinase; and/or nonfermenting Gram-negative bacilli
(NFGNB) resistant to piperacillin-tazobactam, ceftazi-
dime, or imipenem-cilastatin, or producing an extended-
spectrum β-lactamase.
Management of antibiotic therapy
Empiric anti-infective therapy, systematically started at
day 0, took into account the severity of the case and
usually combined piperacillin-tazobactam or imipenem-
cilastatin with amikacin and vancomycin [23], possibly
associated with antifungal therapy (mainly fluconazole)
based on presumed risk factors [25, 29]. Definitive anti-
infective therapy was adapted on the basis of the results
of identification and antibiotic susceptibility testing
(≥48 h). In both situations, therapy was considered ap-
propriate when all cultured organisms (bacteria and
fungi) were targeted. Anti-infective therapy was pre-
scribed by the senior ICU physicians following discus-
sion with the consultant microbiologist on a daily basis.
The following changes were considered to constitute
de-escalation [1]: withdrawal of one agent (β-lactam,
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aminoglycoside, fluoroquinolone, vancomycin, antifungal
agent) or narrowing spectrum of activity (β-lactam
agents) and/or switch from combination to monother-
apy. Discontinuation of unduly administered agents
was also recorded. Changes among cefepime, ceftazidime,
piperacillin-tazobactam, and ticarcillin-clavulanate were
not considered to be significant changes of the spectrum
of coverage [1].
In patients without de-escalation, two situations were
identified according to previous definitions [4]. Main-
tained empiric treatment without modification was called
unchanged therapy [4]. Escalation was defined as addition
or switch to a new broad-spectrum anti-infective agent
(carbapenems, glycopeptides, fluoroquinolones) [4] or up-
grade to broader-spectrum β-lactams [1]. When changes
combined escalation and de-escalation, the patient was
assigned to the escalation group [4]. In summary, a patient
receiving empiric therapy with piperacillin-tazobactam
plus amikacin who was subsequently switched to pipera-
cillin and vancomycin was classified as having withdrawal
of one agent and escalation.
Data collection
All patients’ charts were reviewed. Demographic data
and severity scores (Simplified Acute Physiology Score II
score [30] and Sequential Organ Failure Assessment
[SOFA] score [31]) were recorded on admission to the
ICU. The severity of the underlying medical condition
and the presence of chronic diseases [32] were recorded.
The characteristics of initial surgery were recorded.
The following clinical and severity characteristics were
assessed at day 0, day 3, and day 7 after surgery for pa-
tients still in the ICU [24, 33, 34]: temperature, white
blood cell count (WBC), serum creatinine, and SOFA
score. Patients meeting the following three criteria at
day 3 were arbitrarily defined as improving: (1) a SOFA
score that decreased more than 2 points at day 3 versus
day 0 or a SOFA score of 0 points, (2) a WBC that de-
creased more than 5000/mm3 between day 0 and day 3
or WBC less than 12,500/mm3, and (3) a temperature
decrease greater than 0.5 °C between day 0 and day 3 or
temperature greater than or equal to 36.5 °C and less
than 38.1 °C. Similar analyses were used at day 7 to
compare changes in these criteria between days 3 and 7.
Medical and surgical complications, additional reopera-
tions for persistence of the initial infection or superin-
fections (including MDR organisms), death between
days 3 and 28 following surgery, and discharge from the
hospital were assessed.
Statistical analysis
Results are expressed as median and interquartile range
(IQR) or number and proportion. Statistical significance
was defined as p < 0.05. For statistical analysis, we used
R version 2.14.1 software (R Foundation for Statistical
Computing, Vienna, Austria). For comparisons between
antibiotic strategy groups (de-escalation, no change, or
escalation), we used the χ2 test and Fisher’s exact test for
discrete variables and unpaired Wilcoxon tests for quan-
titative variables. The effect of antibiotic strategy on day
28 mortality was assessed with a Kaplan-Meier survival
curve and tested with a log-rank test.
Three multivariable models were developed (1) to
identify risk factors for de-escalation and (2) to assess
the association between antibiotic strategy (de-escal-
ation, no change, or escalation) and day 28 or in-
hospital mortality. In univariate analysis for these three
models, we used Fisher’s exact tests and Wilcoxon tests.
Unadjusted ORs or HRs were calculated. Variables with
a p value less than 0.2 in univariate analysis were entered
into a multivariate logistic regression model or a Cox
proportional hazards model with backward selection.
For day 28 and in-hospital mortality, the antibiotic strat-
egy was forced until the end of the selection process.
Logistic models were evaluated for discrimination with
the c-statistic and for calibration with the Hosmer-
Lemeshow test.
Results
Epidemiologic and clinical characteristics
During the study period, 311 ICU patients were admit-
ted for the management of HCIAI. Figure 1 displays a
flowchart of patients through the study. Overall, 105 pa-
tients were excluded, resulting in 206 patients for whom
the de-escalation process was analyzed. De-escalation
was performed in 110 patients (53 % of the analyzed
population), and no de-escalation was observed in 96 pa-
tients (47 %) (escalation in 65 patients [32 %] and un-
changed regimen in 31 patients [15 %]). De-escalation
was never performed after discharge from the ICU. The
frequency of de-escalation remained stable over the
study period, ranging between 47 % and 63 % of the ana-
lyzed population (not significant; data not shown). Clin-
ical characteristics were similar at day 0 in both groups
(Table 1). In the non-de-escalation group, a significantly
increased severity was observed in the patients with an
unchanged regimen versus escalation (Table 1).
Microbiologic analysis
Overall, 618 microorganisms from peritoneal samples
were cultured (311 in patients without de-escalation, in-
cluding 101 organisms in the unchanged group and 210
in the escalation group). Similar microbiologic results
were observed between de-escalation and no de-
escalation groups (data not shown), except for lower
proportions of Enterococcus faecium (9 [3 %] versus 18
[7 %] without de-escalation, respectively; p < 0.01) and
non-fermenting Gram-negative bacilli (9 [3 %] versus 22
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[8 %], respectively; p < 0.01). Among patients without
de-escalation, increased proportions of Gram-negative
bacteria and Enterobacteriaceae were observed in pa-
tients with unchanged regimen compared with those
whose regimen was escalated (47 [49 %] versus 69
[37 %], respectively [p < 0.05]; and 38 [40 %] versus 52
[28 %] [p < 0.05]). In the de-escalation group, 23 (21 %)
of 110 patients harbored MDR strains compared with
54 (56 %) of 96 patients in the non-de-escalation
group (p < 0.01) (Table 2).
Anti-infective therapy
De-escalation was performed on a microbiologic basis in
a median delay of 3 days (IQR 2–4) after surgery. Em-
piric treatments and the procedures applied for de-
escalation at day 3 are described in Table 3. Empiric use
of combination therapy, carbapenems, glycopeptides,
and antifungal agents were significantly more frequent
in the de-escalation group. Among antifungal agents,
echinocandins were minimally prescribed for empiric
therapy (six patients in the de-escalation group with dis-
continuation in all but one case and one switch to
azoles, one patient in the non-de-escalation group).
When taking into account the criteria for de-escalation,
we found that 33 patients met three criteria (withdrawing,
narrowing, and switching) in the de-escalation group but
none of those who did not de-escalate. However, two cri-
teria (withdrawing and narrowing) were reported in 17 pa-
tients in the non-de-escalation group. No clinical change
between days 0 and 3 allowed patients who were subse-
quently de-escalated to be differentiated from those who
did not (Table 3).
Determinants of de-escalation in multivariate analysis
were adequate empiric therapy (OR 9.60, 95 % CI 4.02–
22.97, p < 0.001), empiric use of vancomycin (OR 3.39,
95 % CI 1.46–7.87, p = 0.004), carbapenems (OR 2.64,
95 % CI 1.01–6.91, p = 0.04), and aminoglycosides (OR
2.31, 95 % CI 1.08–4.94, p = 0.03), while presence of
NFGNB (OR 0.28, 95 % CI 0.09–0.89, p = 0.03) and
presence of MDR bacteria (OR 0.21, 95 % CI 0.09–0.52,
p < 0.001) were the risk factors for non-de-escalation
(c-index 0.880, 95 % CI 0.832–0.928, Hosmer-Lemeshow
test p = 0.14) (Table 4).
At day 3, no difference was observed between patients
with an unchanged regimen and those who underwent
escalation, except for the higher proportions of
105 patients excluded from the analysis
Negative microbiologic samples (n=7)
Death during the first three days (n=22)
Patients discharged alive during the first three days (n=10)
Patients who underwent early reoperation (n=66) 
311 patients admitted in ICU  
for postoperative peritonitis 
De-escalation in
110 (53%) patients 
No de-escalation in
96 (47%) patients






Fig. 1 Flowchart of the 206 patients studied. ICU intensive care unit
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aminoglycosides and antifungal therapy and the very
low proportion adequate empiric therapy (Table 3).
Clinical evaluation following de-escalation
When comparing the patients who were de-escalated
and those who did not de-escalate, we found no significant
difference between days 3 and 7 (Table 5). In addition, no
significant difference in morbidity or mortality criteria was
observed between these two groups.
No significant differences in morbidity or mortality
criteria were observed between patients who underwent
escalation and those with an unchanged regimen, except
for significantly increased proportions of surgical com-
plications and reoperations in patients with an un-
changed regimen. The risk factors for death at day 28
following surgery in a Cox model are presented in
Table 6. The survival rate expressed by a Kaplan-Meier
curve was similar between groups (log-rank test p value
0.176) (Fig. 2).
The risk factors of in-hospital mortality on multivari-
ate analysis were the emergency initial surgery (OR 2.81,
95 % CI 1.30–6.05, p = 0.008) and SOFA score on ad-
mission (OR 1.42, 95 % CI 1.24–1.62, p < 0.001), while
a decreased SOFA score at day 3 had a protective value
(OR 0.14, 95 % CI 0.06–0.31, p < 0.001) (c-index 0.852,
95 % CI 0.794–0.910, Hosmer-Lemeshow test p = 0.28).
Discussion
In this single-center observational study, de-escalation
was performed in 53 % of patients treated for HCIAI.
De-escalation concerned both antibacterial and antifun-
gal therapies. The de-escalation procedure did not mod-
ify outcome. No initial clinical characteristic allowed
identification of patients who were subsequently de-
escalated. The presence of MDR bacteria and NFGNB as
well as initial monotherapy were the most relevant fac-
tors limiting de-escalation. No emergence of resistant
organisms was observed following de-escalation in the
patients who underwent subsequent reoperation.
In the absence of data in the literature, we consider
that our results provide an encouraging perspective for
antibiotic de-escalation in ICU patients with abdominal
Table 1 Demographic and clinical characteristics of the 206 patients with or without subsequent antibiotic de-escalation
Characteristic De-escalation (n = 110) No de-escalation (n = 96) Escalation (n = 65) No change (n = 31)
Male sex, n (%) 61 (55) 56 (58) 35 (54) 21 (68)
Age, years, median (IQR) 61 (47–72) 66 (51–75)a 63 (47–75) 70 (58–77)
Comorbidities
Fatal underlying disease 30 (27) 32 (33) 21 (32) 11 (35)
Cancer, n (%) 37 (34) 36 (38) 23 (35) 13 (42)
Diabetes, n (%) 17 (15) 15 (16) 9 (14) 6 (19)
Time since initial surgery, days, median (IQR) 7 (5–12) 7 (4–10) 6 (3–9) 8 (5–10)
Antibiotic therapy before reoperation, n (%) 73 (66) 68 (71) 47 (72) 21 (68)
Broad-spectrum interim antibiotic, n (%) 34 (31) 37 (39) 27 (42) 10 (32)
Intraoperative diagnosis
Anastomotic leakage, n (%) 45 (41) 27 (28) 19 (29) 8 (26)
Perforation or ischemia, n (%) 33 (30) 36 (38) 20 (31) 16 (52)a#
Purulent collection, n (%) 19 (17) 17 (18) 13 (20) 4 (13)
No cause, n (%) 19 (17) 20 (21) 15 (23) 5 (16)
Contamination below transverse mesocolon, n (%) 82 (75) 74 (77) 50 (77) 24 (77)
Characteristics at the time of ICU admission
Bacteremia, n (%) 26 (24) 17 (18) 14 (22) 3 (10)
SAPS II score, median (IQR) 45 (34–54) 47 (35–57) 44 (34–56) 51 (42–61)a#
SOFA score, median (IQR) 7 (4–9) 8 (4–10) 7 (4–9) 9 (6–10)
Hemodynamic failureb, n (%) 65 (59) 65 (68) 41 (63) 24 (77)
Respiratory failureb, n (%) 54 (49) 40 (42) 26 (40) 14 (45)
Renal failureb, n (%) 21 (19) 18 (19) 13 (20) 5 (16)
IQR interquartile range, SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure Assessment
Patients without de-escalation were also analyzed in terms of subsequent antibiotic escalation or no change. Results are expressed as number and proportions or
median (IQR)
ap < 0.05 versus de-escalation
bSOFA score of 3 or 4 for each organ
#p < 0.05 versus escalation
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sepsis. However, some limitations should be considered.
Only 110 (35 %) of 311 patients treated for HCIAI were
de-escalated. This highly selected population and the in-
clusion and exclusion criteria could be considered to
constitute a weakness, but they allow selection of cases
in which de-escalation is possible. Our local policy for
empiric and definitive antibiotic use and the local char-
acteristics of microbial flora must be considered cau-
tiously and cannot be generalized. The long study
duration may also have led to changes in the case mix or
in antibiotic susceptibility patterns over time, although
our analysis did not confirm this hypothesis. Another
major limitation in the interpretation of our results is
the lack of assessment of the quality of source control.
The exclusion of patients undergoing early reoperation
probably limited the importance of this issue. The absence
of consensual definitions for de-escalation is another issue
to be considered. The quality of de-escalation could be
considered incomplete in many patients in whom there is
room for improvement, and further reduction of antibiotic















Fig. 2 Kaplan-Meier survival curves of patients with de-escalation, without any change, and with escalation
Table 2 Multidrug-resistant bacteria cultured from peritoneal fluid of patients with or without subsequent antibiotic de-escalation
Microorganisms De-escalation No de-escalation Escalation No change
Total number of multidrug-resistant bacteria, n (%) 29 (9) 74 (24)a 58 (28) 16 (16)b
Gram-positive bacteria, n (%) 15 (5) 39 (13)a 33 (16) 6 (6)b
Enterococci, n (%) 3 (1) 9 (3) 7 (3) 2 (2)
Staphylococci, n (%) 12 (4) 29 (9) 25 (12) 4 (4)
Staphylococcus aureus, n (%) – 8 (3) 6 (3) 2 (2)
Gram-negative bacteria, n (%) 14 (5) 35 (11)a 25 (12) 10 (10)
Enterobacteriaceae, n (%) 10 (3) 24 (8) 18 (9) 6 (6)
Escherichia coli, n (%) 1 (0) 11 (4) 8 (4) 3 (3)
Enterobacter spp., n (%) 5 (2) 9 (3) 8 (4) 1 (1)
Nonfermenting Gram-negative bacilli, n (%) 3 (1) 11 (4) 7 (3) 4 (4)
Pseudomonas spp., n (%) 2 (1) 6 (2) 4 (2) 2 (2)
Total number of cultured bacteria, n 307 311 210 101
Among the 96 patients without de-escalation, the results were analyzed in terms of subsequent antibiotic escalation or no change
ap < 0.01 versus de-escalation
bp < 0.05 versus escalation
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Observational and retrospective studies have suggested
that the de-escalation strategy is a safe approach in pa-
tients with severe sepsis or septic shock [10–12, 15, 18,
19, 22, 35]. In recent European observational trials, the
de-escalation rate ranged between 12.8 % of cases in a
multicenter study in 41 French ICUs [35] and 64 % in a
single-center analysis focused on patients with severe
sepsis and septic shock [15]. Some prospective obser-
vational studies have suggested that mortality rates
were at least not worse than those observed in patients
not de-escalated [16, 36–38]. In these reports, the
lengths of ICU and hospital stay were not significantly
different [36, 37]. Other authors have reported that de-
escalation therapy could even significantly improve the
prognosis [4, 13, 39].
Prospective randomized trials addressing the issue of
de-escalation are extremely rare. In a cohort of 290 pa-
tients treated for VAP, Micek et al. reported a decreased
duration of antibiotic therapy and no significant differ-
ences in terms of secondary episodes of VAP and hos-
pital mortality [37]. In a group of 116 patients with
severe sepsis either assigned or not to de-escalation,
Table 3 Anti-infective regimens in patients with or without de-escalation and clinical characteristics at day 3
De-escalation (n = 110) No de-escalation (n = 96) Escalation (n = 65) No change (n = 31)
Empiric antibiotic therapy
Monotherapy, n (%) 13 (12) 32 (33)a 20 (31) 12 (29)
Combination of two drugs, n (%) 40 (36) 34 (35) 26 (40) 8 (26)
Combination of three drugs or more, n (%) 57 (49) 30 (33)b 19 (29) 11 (35)
Carbapenem, n (%) 35 (32) 15 (16)a 10 (15) 5 (16)
Piperacillin-tazobactam, n (%) 67 (61) 60 (63) 40 (62) 20 (65)
Vancomycin, n (%) 57 (52) 23 (24)a 15 (23) 8 (26)
Aminoglycosides, n (%) 59 (54) 33 (34)a 27 (42) 6 (19)b
Fluoroquinolones, n (%) 6 (5) 11 (11) 10 (15) 1 (3)
Antifungal therapy, n (%) 47 (43) 23 (24)a 11 (17) 12 (39)b
Azoles, n (%) 41 (37) 20 (21)a 9 (14) 11 (35)b
Adequate empiric therapy, n (%) 100 (91) 37 (39)a 9 (14) 28 (90)c
Reevaluation of antibiotic therapy
Discontinuation of carbapenemsd, n (%) 27/35 (77) 4/15 (27) 4/10 (40) –
Discontinuation of piperacillin-tazobactamd, n (%) 50/67 (75) 25/60 (42) 25/40 (63) –
Discontinuation of vancomycind, n (%) 46/57 (81) 6/23 (26) 6/15 (40) –
Discontinuation of aminoglycosidesd, n (%) 54/59 (92) 21/33 (64) 21/27 (78) –
Discontinuation of fluoroquinolonesd, n (%) 2/6 (33) 6/11 (55) 6/10 (60) –
Discontinuation of antifungal agent d, n (%) 23/47 (49) 4/23 (17) 4/11 (36) –
Withdrawal of at least one agent, n (%) 110 (100) 42 (47)a 42 (65) –
Narrowing spectrum, n (%) 74 (67) 18 (19)a 18 (28) –
Switch to monotherapy, n (%) 54 (49) 7 (7)a 7 (11) –
Interruption of unnecessary agent, n (%) 78 (71) 20 (21)a 20 (31) –
Clinical changes between days 0 and 3
Changes in SOFA score, median (IQR) −2 (−4 to -1) −2 (−4 to 0) −2 (−4 to 0) −2 (−3 to 0)
Decreased SOFA score, n (%) 69 (63) 57 (59) 38 (58) 19 (61)
Decreased temperature, n (%) 69 (63) 64 (67) 41 (63) 23 (74)
Decreased WBC, n (%) 38 (35) 32 (33) 23 (35) 9 (29)
Clinical improvement at day 3, n (%) 17 (15) 18 (19) 14 (22) 4 (13)
IQR interquartile range, SOFA Sequential Organ Failure Assessment, WBC white blood cell count
Among those without de-escalation, the results were analyzed in terms of subsequent antibiotic escalation or no change. Results are expressed as number and
proportion of the total number of patients
ap < 0.01 versus de-escalation
bp < 0.05 versus de-escalation
cp < 0.01 versus escalation therapy
dProportions are expressed as the number of discontinuations of the drug to the total number of patients empirically receiving this class of drug
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Leone et al. demonstrated that de-escalation was inferior
to continuation of the initial antibiotic therapy with
length of stay as the primary outcome parameter [40].
Furthermore, antibiotic use was higher in the de-
escalation group with a higher number of superinfec-
tions in the de-escalation group, but mortality was
similar in the two groups [40].
Only four retrospective, single-center, observational
studies have described de-escalation practices for pa-
tients with peritonitis [14, 18, 21, 22], including between
113 and 229 patients, 10–38 % of whom presented with
peritonitis. Although the observed de-escalation rate was
23–58 % in this population, none of these studies pro-
vided any information on the outcome of de-escalated
patients. Our analysis is the first to focus on this surgical
population, and our results suggest that de-escalation is
safe and does not change the clinical outcome. On the
basis of our results, a prospective multicenter study
would appear to be feasible.
Obstacles to de-escalation have been clearly identified
in the literature [20]. The lack of appropriate empiric
therapy is the first point to be considered [13, 22]. A
high rate of MDR bacteria is an obvious reason for inad-
equate empiric therapy and consequently a recognized
factor for limited de-escalation [20]. However, although
a recent analysis suggested that polymicrobial infection
was a negative factor for de-escalation [20], we did
not observe this trend in the patients in our present
study. Narrow-spectrum empiric therapy is obviously
another important determinant limiting the frequency
of de-escalation [22]. However, narrow-spectrum em-
piric therapy is not an issue in intra-abdominal infec-
tions in which treatment should at least target
anaerobes and Enterobacteriaceae [41]. On the con-
trary, monotherapy has been proposed for the treat-
ment of peritonitis [41], and this policy could be a
limitation on de-escalation [18].
Poor or absent clinical improvement is another factor
limiting de-escalation. In the present study, clinical and
laboratory parameters of day 3 were unable to differenti-
ate patients in whom de-escalation would be feasible
and those in whom de-escalation could not be per-
formed. Interestingly, Garnacho-Montero et al. reported
lower SOFA scores at the time of de-escalation [4], sug-
gesting that the criteria for de-escalation may change
from one population to another. This also means that
prescribers should rely on microbiologic samples and
the laboratory results more than any other criteria. The
confidence of prescribers in their initial therapy is also
based on two parameters that have been only minimally
Table 4 Uni- and multivariate analyses of risk factors for de-escalation






odds ratio (95 % CI)
p valuea Adjusted
odds ratio (95 % CI)
p value
At time of admission
Age, years 61 (47–72) 66 (51–75) 0.98 (0.97–0.99) 0.049 – –
Emergency surgery 37 (34) 44 (46) 0.60 (0.34–1.05) 0.087
Anastomotic leakage 45 (41) 27 (28) 1.76 (0.98–3.17) 0.058 – –
Empiric antibiotic monotherapy 13 (12) 32 (33) 0.26 (0.13–0.54) <0.01 – –
Initial use of carbapenems 35 (32) 15 (16) 2.52 (1.27–4.98) 0.009 2.64 (1.01–6.91) 0.047
Initial use of vancomycin 57 (52) 23 (24) 3.41 (1.87–6.21) <0.0001 3.39 (1.46–7.87) 0.004
Initial use of aminoglycosides 59 (54) 33 (34) 2.20 (1.25–3.88) 0.007 2.31 (1.08–4.94) 0.031
Initial use of fluoroquinolones 6 (5) 11 (11) 0.44 (0.15–1.22) 0.134
Initial use of antifungal agents 47 (43) 23 (24) 2.36 (1.29–4.32) 0.005 – –
At day 3
Presence of Enterococcus faecium 8 (7) 18 (19) 0.33 (0.14–0.82) 0.019 – –
Presence of streptococci 31 (28) 17 (18) 1.82 (0.93–3.55) 0.098 – –
Presence of staphylococci 25 (23) 35 (36) 0.51 (0.27–0.94) 0.032 – –
Presence of NFGNB 8 (7) 22 (23) 0.26 (0.11–0.62) 0.002 0.28 (0.09–0.89) 0.031
Presence of MDR strains 23 (21) 54 (56) 0.20 (0.11– 0.37) <0.0001 0.21 (0.09–0.52) 0.0007
Presence of fungi 30 (27) 41 (43) 0.50 (0.28–0.90) 0.027 – –
Adequate empiric therapy 100 (91) 37 (39) 15.95 (7.38–34.40) <0.0001 9.60 (4.02–22.97) <0.0001
MDR multidrug-resistant, NFGNB nonfermenting Gram-negative bacilli
The c-index of the final model is 0.880 (95 % CI 0.832–0.928), and the Hosmer-Lemeshow test p value is 0.14
ap values are derived from Fisher’s exact test or Wilcoxon test
Montravers et al. Critical Care  (2016) 20:83 Page 8 of 12
assessed in the literature: adequacy of source control
and pharmacokinetics of anti-infective agents.
Several reports have indicated early improvement in
patients who underwent de-escalation. Paskovaty et al.,
in a cohort of adult patients with cancer admitted to the
ICU for severe sepsis, reported a significantly decreased
SOFA score on day 5 [42]. Two studies of patients with
nosocomial pneumonia and ICU-acquired pneumonia
reported early decreased SOFA and Acute Physiology
and Chronic Health Evaluation II scores in the de-
Table 5 Clinical presentation at day 7 of empiric therapy and outcome in patients with or without de-escalation
De-escalation (n = 110) No de-escalation (n = 96) Escalation (n = 65) No change (n = 31)
Definitive anti-infective therapy
Monotherapy, n (%) 64 (58) 21 (22) 9 (14) 12(29)a
Combination of two drugs, n (%) 33 (30) 39 (41) 31 (48) 8 (26)b
Combination of three drugs or more, n (%) 13 (12) 36 (38) 25 (38) 11 (35)
Use of carbapenems, n (%) 5 (5) 23 (24)a 18 (28) 5 (16)
Use of piperacillin-tazobactam, n (%) 28 (25) 39 (41)b 19 (29) 20 (65)a
Use of vancomycin, n (%) 11 (10) 41 (43)a 33 (51) 8 (26)b
Use of antifungals, n (%) 29 (26) 43 (45)a 31 (48) 12 (39)
Use of azoles, n (%) 28 (25) 39 (41)b 28 (43) 11 (35)
Use of echinocandins, n (%) 1 (1) 3 (3) 3 (5) –
Duration of anti-infective therapy, days, median (IQR) 10 (10–14) 10 (10–14) 10 (10–14) 10 (10–14)
Clinical changes between days 3 and 7
Number of cases at day 7 91 75 51 24
Changes in SOFA scorec, median (IQR) −1 (−3 to 0) −2 (−4 to 0) −2 (−4 to 0) −2 (−4 to 0)
Decreased SOFA scorec, n (%) 57 (63) 48 (64) 35 (54) 13 (42)
Decreased temperaturec, n (%) 38 (42) 36 (48) 27 (42) 9 (29)
Decreased WBCc, n (%) 31 (34) 17 (23) 12 (18) 5 (16)
Clinical improvement at day 7c, n (%) 16 (18) 9 (12) 9 (14) –
Discharge between days 3 and 7, n (%) 20 (22) 15 (20) 10 (20) 5 (21)
Death between days 3 and 7, n (%) 1 (1) 3 (4) 2 (4) 1 (4)
Medical complications 12 (12) 14 (16) 6 (10) 8 (29)
Surgical complications 26 (25) 21 (24) 10 (17) 11 (39)b
Reoperation, n (%) 38 (35) 35 (36) 19 (29) 16 (51)b
Time to reoperation, days, median (IQR) 6 (5–9) 6 (5–8) 5 (4–8) 7 (6–10)
Superinfection on subsequent reoperationd, n (%) 23 (61) 23 (66) 13 (68) 10 (63)
Emergence of MDR strainsd, n (%) 21 (55) 20 (57) 11 (58) 9 (56)
Emergence of ESBL Enterobacteriaceaed, n (%) 5 (13) 5 (14) 3 (16) 2 (13)
Emergence of MDR NFGNBd, n (%) 9 (24) 5 (14) 2 (11) 3 (19)
Emergence of MRSAd, n (%) 9 (24) 8 (23) 6 (32) 2 (13)
Duration of mechanical ventilatione, days, median (IQR) 7 (3–13) 7 (3–11) 7 (2–10) 7 (3–15)
ICU length of staye, days, median (IQR) 12 (8–20) 12 (8–21) 12 (8–21) 14 (5–23)
Survival at day 28, n (%) 91 (83) 72 (75) 51 (78) 21 (68)
ICU mortality rate, n (%) 23 (21) 32 (33)b 18 (28) 14 (45)
Hospital mortality rate, n (%) 25 (23) 33 (34) 19 (29) 14 (45)
ESBL extended-spectrum β-lactamase, ICU intensive care unit, IQR interquartile range, MDR multidrug-resistant, MRSA methicillin-resistant Staphylococcus aureus,
NFGNB nonfermenting Gram-negative bacilli, SOFA Sequential Organ Failure Assessment, WBC white blood cell count
Among those without de-escalation, the results were analyzed in terms of subsequent antibiotic escalation or no change
ap < 0.01 versus escalation therapy
bp < 0.05 versus escalation therapy
cResults expressed as number of patients at day 7 in the same group
dResults expressed as number of patients who underwent reoperation in the same group
eResults calculated for ICU survivor patients
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escalation groups [43, 44]. On the contrary, the inci-
dence of organ failure at day 7 was similar in our pa-
tients with or without de-escalation. There is no obvious
explanation for this discrepancy, but medical and surgi-
cal patients with sepsis may respond in different ways.
The rate of antibiotic escalation, although regularly
discussed, is rarely assessed in the literature. In re-
cent papers, this rate has ranged between 6.6 % and
7.9 % [18, 22]. However, Garnacho et al. reported es-
calation in 19 % of patients despite adequate empiric
therapy [4]. The mortality rate in this cohort was sig-
nificantly increased compared with de-escalation or
unchanged therapy (42.9 % versus 27.4 % and 32.6 %,
respectively; p = 0.006) [4], while Gonzales et al. re-
ported that escalation did not induce any significant
change in prognosis [22]. In these two studies, the
heterogeneous case mix resulted in complex analysis
of these data. Few studies have reported the fre-
quency and prognosis of escalation in peritonitis, but
the effect of escalation appears to be less obvious in
the present cohort.
Several beneficial effects of de-escalation have been
hypothesized, including preservation of the patient’s
ecology and decreased emergence of MDR pathogens [3,
45]. However, these assumptions have never been clearly
demonstrated. In the present study, we did not observe
any significant change in the emergence of resistant
pathogens in either the intra-abdominal site or extra-
abdominal sites following de-escalation. This is not
surprising, as the detection of emerging MDR organisms
was not a specific goal of this study and changes of gut
microbiota of our patients were not targeted. Similarly,
de-escalation does not change the overall duration of
therapy. This point, already mentioned in other studies
[22], was also observed in our present study.
An abundant literature exists regarding assessment of
antibiotic de-escalation, but few data are available for an-
tifungal agents. Several reports in candidemia or invasive
candidiasis suggest that antifungal de-escalation is feasible
[46–48], but no study has specifically addressed the issue
of intra-abdominal infections. Unwarranted antifungal
prescription is frequently reported in ICU patients, which
raises both ecological and financial concerns [49]. De-
escalation and/or discontinuation of antifungal treatments
could be proposed more frequently. Our data suggest that
antifungal de-escalation could be feasible with no specific
complications.
Conclusions
De-escalation is a reasonable option, even in patients
with polymicrobial infections such as HCIAI. However,
MDR bacteria and NFGNB remain major obstacles to
implementation of de-escalation. The prescriber must
consider whether the determinants of success have
been met, especially an adequate empiric therapy.
Although our results are reassuring, this strategy needs
to be confirmed in a multicenter, randomized, pro-
spective trial.
Table 6 Uni- and multivariate analyses of risk factors for 28-day mortality
Univariate analysis Multivariate analysis
Death at day
28 (n = 43)
Survival at day
28 (n = 163)
Unadjusted hazard
ratio (95 % CI)
p valuea Adjusted hazard
ratio (95 % CI)
p value
Age, years 69 (56–78) 62 (46–72) 1.022 (1.003–1.042) 0.023 1.034 (1.011–1.059) 0.004
Emergency surgery 24 (56) 57 (35) 2.072 (1.135–3.783) 0.015 – –
Surgery below the mesocolon 28 (65) 128 (79) 0.561 (0.299–1.050) 0.075 0.427 (0.215–0.848) 0.015
SOFA score 10 (7–11) 7 (4–9) 1.261 (1.153–1.380) <0.0001 1.291 (1.168–1.427) <0.0001
SAPS II score 52 (45–61) 44 (32–53) 1.039 (1.019–1.060) <0.0001 – –
Initial use of piperacillin-tazobactam 22 (51) 105 (64) 0.636 (0.350–1.157) 0.117 – –
Empiric antifungal therapy 21 (49) 49 (30) 1.980 (1.089–3.601) 0.029 – –
Other Enterobacteriaceaeb 5 (12) 34 (21) 0.538 (0.212–1.366) 0.195 0.342 (0.1219–0.961) 0.0419
Presence of Candida spp. 19 (44) 52 (32) 1.569 (0.859–2.865) 0.150 2.641 (1.3471–5.179) 0.0047
Decreased SOFA score at day 3 17 (40) 109 (67) 0.372 (0.202–0.686) 0.0015 0.311 (0.1632–0.593) 0.0004
Antibiotic strategy 0.189
De-escalation 19 (44) 91 (56) 0.488 (0.227–1.051) 0.566 (0.2503–1.278) 0.171
No change 10 (23) 21 (13) Reference Reference Reference
Escalation 14 (33) 51 (31) 0.627 (0.278–1.411) 0.508 (0.2154–1.198) 0.122
SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure Assessment
ap values are from Fisher exact tests or Wilcoxon tests
bOther Enterobacteriaceae: analysis of all Enterobacteriaceae except Escherichia coli, Klebsiella spp., and Enterobacter spp.
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Key messages
 De-escalation is a reasonable option, even in
polymicrobial infections such as health
care-associated intra-abdominal infections.
 Multidrug-resistant bacteria and nonfermenting
Gram-negative bacilli remain a major obstacle in
de-escalation.
 The key determinants for de-escalation are susceptible
microorganisms and adequate empiric therapy.
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